The Avoca Group Selects Strategic Partner, Sitrof Technologies
Sitrof Technologies
, a provider of IT and document management solutions for the life sciences industry, and
The Avoca Group
, a consulting and research organization specializing in clinical outsourcing and alliance management, today announced a strategic partnership specifically tailored for the life sciences industry.
“The Avoca Group provides comprehensive alliance and relationship management consulting services to the life sciences industry and we are always in search of best-of-breed solutions,” said Avoca President Patricia Leuchten. “By partnering with Sitrof Technologies our clients and Avoca Quality Consortium member companies will benefit as we streamline our processes through the application of the latest technologies available. In addition, as part of the partnership, Avoca and Sitrof will proactively identify ways that technology enablers can support Avoca's mission to help their clients build, measure and manage business relationships in the life sciences area."
Sitrof Technologies’ award-winning solutions have been deployed in dozens of life sciences companies including CROs, IRBs and other life sciences service partners in clinical trials, quality management and regulatory affairs. Founding partners Dan Wheeler and Bryan Reynolds have built a highly successful IT services business helping life sciences companies streamline and automate their processes.
“Unstructured content generation and the need for outsourcing are both growing at tremendous rates within life sciences companies, with no slow down in sight,” said Reynolds. “By working with The Avoca Group and Sitrof Technologies, life sciences companies can be assuredthey are implementing best practices in relationship management and qualitymanagement based on the most up-to-date, validated technologies and Business Process Management (BPM) platforms.”
Related Links:
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025